Xeltis has announced promising 12-month clinical data from its pivotal trial of aXess™, a novel implant designed for hemodialysis vascular access, which shows a 79% secondary patency rate and a low 1.3 patency-related reintervention rate per patient year. This study, involving 120 patients across 22 sites in Europe, highlights aXess™’s superior performance compared to conventional arteriovenous grafts (AVGs), particularly in complex patient populations, where 69% had prior central venous catheter use and failed fistulas.

The significance of these findings lies in aXess™’s durability and infection resistance. The study reported a mere 3% access-related infection rate, starkly lower than the 22% for central venous catheters and 9% for AVGs. These results suggest that aXess™ not only reduces the frequency of reinterventions but also enhances patient safety and quality of life by minimizing complications associated with traditional vascular access methods. The technology, built on the Restorex™ polymer platform, enables the implant to transform into living tissue, thereby addressing longstanding challenges in vascular access.

The implications for the field are profound. With CE mark approval now secured, Xeltis is positioned to commercialize aXess™, marking a potential shift in vascular access strategies for hemodialysis patients. This advancement could redefine treatment protocols, significantly impacting drug development timelines for related therapies by establishing a new standard of care that prioritizes long-term efficacy and patient-centered outcomes. The ability to provide a living vessel that integrates with the patient’s own tissue may also open avenues for further research into regenerative medicine applications in vascular and cardiovascular diseases.

Source: globenewswire.com